FDA Seeks More Authority Over Drug Direct-to-Consumer Advertising
The FDA is asking for expanded authority over direct-to-consumer (D2C) drug advertising in its 2027 budget proposal, including expanding the definition of misbranded drugs and more directly targeting compounded drugs.
Objective Facts
The FDA is asking for expanded authority over direct-to-consumer (D2C) drug advertising in its 2027 budget proposal, including expanding the definition of misbranded drugs and more directly targeting compounded drugs under the Food, Drug, and Cosmetic (FD&C) Act. The proposal would classify drug ads as misbranded if they lack fair balance, misrepresent FDA approval, or overstate a drug's efficacy. Last year, President Trump ordered the agency to ensure companies provide balanced information on the benefits and risks of drugs in DTC ads, and days later, the agency published letters alleging violations of federal pharma marketing rules by companies including Bristol Myers Squibb, Eli Lilly and Novartis. On March 31, 2026, Senators Dick Durbin (D-IL) and Roger Marshall (R-KS) urged FDA by letter to require pre-submission of certain DTC drug ads before they air, highlighting that the current environment warrants greater and more aggressive use of FDA's pre-review authority particularly for high-risk products. Since September 2025, FDA has sent more than 100 warning letters to both pharmaceutical manufacturers and telehealth companies for alleged false and misleading advertising, reflecting renewed scrutiny of how companies depict clinical efficacy and safety in their claims.
Left-Leaning Perspective
HHS Secretary Robert F. Kennedy Jr. and patient advocacy organizations strongly support FDA expansion of authority over direct-to-consumer drug advertising. HHS Secretary Robert F. Kennedy Jr. stated 'Pharmaceutical ads hooked this country on prescription drugs' and committed to 'shut down that pipeline of deception and require drug companies to disclose all critical safety facts in their advertising' to break the cycle of overmedicalization that drives America's chronic disease epidemic. Patient advocacy groups including Generation Patient support the Protecting Patients from Deceptive Drug Ads Act, introduced by Senators Durbin (D-IL) and Marshall (R-KS), arguing that pharmaceutical marketers have shifted their budgets toward social media and paid influencers while FDA regulation has lagged. Progressives and public health advocates cite research supporting tighter restrictions on drug advertising. Public health advocates argue that such ads encourage the use and overuse of expensive new medications, even when existing, cheaper drugs work as effectively. The American Medical Association has been calling for a ban on direct-to-consumer advertising of prescription drugs for years, citing drug marketing's role in higher drug prices. NYU professor Jennifer Pomeranz, who worked as a pharmaceutical defense lawyer early in her career, notes the analysis is 'especially timely given the evolving political landscape and bipartisan support for protecting patients from deceptive drug ads'. Left-leaning coverage emphasizes the need for FDA authority to require pre-review of ads before dissemination and to expand oversight of social media promotions. Durbin and Marshall urged FDA to use existing authority to require certain advertisements to undergo pre-submission before dissemination, with FDA having tools to seek changes on the front end before patients are inundated with harmful content. The left downplays First Amendment concerns raised by industry, focusing instead on the documented harms of misleading advertising and gaps in FDA oversight of telehealth platforms and influencer marketing.
Right-Leaning Perspective
Conservative legal scholars and the pharmaceutical industry argue that FDA's expansion of authority over DTC advertising violates First Amendment protections for commercial speech and exceeds the agency's statutory authority. The Washington Legal Foundation contends that pharmaceutical marketing including DTC advertising is protected by the First Amendment and that while FDA has authority to combat truly deceptive ads, its broad enforcement actions threaten legitimate commercial speech without clear evidence, arguing 'Pharmaceutical marketing, including DTC advertising, is protected by the First Amendment—full stop'. Sidley Austin LLP notes that many recent FDA letters raise issues previously viewed as settled in light of First Amendment limitations on FDA's ability to regulate truthful and non-misleading information, and FDA's enforcement efforts may therefore face challenges from industry and other stakeholders. Right-leaning analysis questions the legal and practical basis for expanded FDA authority. The Washington Legal Foundation argues that while HHS Secretary Kennedy wants to eradicate drug ads, neither he nor Congress may do so, and the cost for a company to invent a new drug and bring it to market is well north of a billion dollars, with advertising necessary to market a drug on a large enough scale to make safety and efficacy testing economically feasible. Skadden Arps notes that FDA's apparent assumption that every pharmaceutical manufacturer is potentially releasing noncompliant advertising seems inconsistent with common industry practice and the reality of current DTC advertising where it is common practice to seek voluntary advisory opinions before launching major ad campaigns. Right-leaning coverage emphasizes statutory and constitutional limits on FDA authority and disputes the characterization of the 1997 regulatory framework as a loophole. The Washington Legal Foundation contends that HHS and FDA have repeatedly and inaccurately referred to a 'loophole' established in 1997, and that an FDA regulation requiring dramatically expanded disclosure of side effects and contraindications would not survive a legal challenge alleging the agency is exceeding its statutory authority. The right downplays evidence of harms from advertising and questions whether enforcement resources could effectively address alleged problems.
Deep Dive
The story's specific angle concerns whether the FDA should seek and Congress should grant expanded statutory authority over DTC drug advertising—particularly the power to require pre-publication review of ads, classify ads with inadequate risk disclosures as misbranded, and more directly regulate compounded drug advertising. This represents an intensification of enforcement that began in September 2025 following President Trump's executive order directing stronger enforcement of existing regulations. The factual foundation is that the FDA already has some authority under existing law, particularly 21 U.S.C. § 353c (pre-review authority that Congress granted in 2007 but FDA has never used), yet both the Trump administration and Democratic lawmakers are pushing for either broader statutory authority or more aggressive use of existing authority. The FDA's 2027 budget proposal seeks to codify specific violations into law—making it unnecessary to prove violations case-by-case—rather than relying on the current framework where FDA must build individual legal cases. The left argues current enforcement is insufficient because companies view fines as business costs; the right argues FDA already has adequate tools and is mischaracterizing the regulatory landscape. What each side gets right and what they miss: The left accurately identifies that voluntary industry compliance has limitations and that telehealth platforms and influencers operate in genuine regulatory gray areas. However, left-leaning coverage somewhat overstates the novelty of the problem—FDA has sent enforcement letters for decades and research on DTC advertising harms dates to the 1980s-1990s. The right correctly notes that FDA possesses existing statutory authority for pre-review and that current regulations are already detailed and comprehensive. However, right-leaning analysis underestimates the practical enforcement gap, particularly for social media content and compounded drugs that may not fit traditional regulatory frameworks. Both sides largely ignore the difficult question of consumer autonomy—whether restricting advertising respects or undermines patients' ability to seek information about available treatments. What to watch: The 2027 budget proposal must navigate Congressional approval; there is bipartisan support for addressing egregious violations (influencer payments, telehealth deception) but constitutional questions about expanded compelled disclosure remain unresolved. The Supreme Court's recent commercial speech jurisprudence (Central Hudson standard) may limit how much FDA can require without demonstrating it directly advances substantial government interests and is no more extensive than necessary. Additionally, the FDA's resource constraints—particularly staffing cuts to the Office of Prescription Drug Promotion—create practical limits on enforcement regardless of new authority.